Jeffrey Rockoff, MD
Pediatric Allergy/Immunology · Buffalo, NYNPI 1902873839
Payments from drug & device makers
Across 568 payments — averaging $35.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- Genentech USA, Inc.$5K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$1K
- Pfizer$711
- plus $4K from 29 others
What the payments were for
- Consulting fees$6,86034%
- Travel & lodging$3662%
- Food & beverage$12,83663%
- Education$2961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 89 | $5,664 |
| Genentech USA, Inc. | 34 | $5,223 |
| GSK | 103 | $1,769 |
| Regeneron Healthcare Solutions, Inc. | 87 | $1,676 |
| AstraZeneca | 52 | $1,317 |
| Pfizer | 30 | $711 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $545 |
| Optinose US, Inc. | 12 | $382 |
| Grifols USA, LLC | 19 | $375 |
| Amgen(2 entities) | 15 | $341 |
| Alk-abello, Inc | 14 | $325 |
| Kaleo, Inc. | 15 | $267 |
| Biocryst US Sales Co., LLC | 8 | $255 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $223 |
| Boehringer Ingelheim | 13 | $216 |
| Teva Pharmaceuticals USA, Inc. | 12 | $189 |
| CSL Behring | 7 | $171 |
| Pharming Healthcare, Inc. | 7 | $168 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Octapharma USA, Inc. | 3 | $67 |
| Incyte Corporation | 2 | $52 |
| Covis Pharma GmbH | 3 | $46 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Phadia US Inc. | 1 | $31 |
| Mylan Specialty L.p. | 2 | $29 |
| USWM, LLC | 1 | $29 |
| Blueprint Medicines Corporation | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Biocryst Pharmaceuticals, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $18 |
| Bio Products Laboratory USA, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| AbbVie | 1 | $16 |
| Organon | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,357 in reported general payments places this provider in the 70th percentile of 51 pediatric allergy/immunology providers in New York.
See all pediatric allergy/immunology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 19 | $914,248 |
| Dupixent PenDupilumab | 48 | $184,101 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $97,281 |
| Dupixent SyringeDupilumab | 16 | $80,030 |
| NucalaMepolizumab | 18 | $59,934 |
| Spiriva RespimatTiotropium Bromide | 45 | $36,033 |
| Qvar RedihalerBeclomethasone Dipropionate | 79 | $33,630 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 155 | $27,118 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,144 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $14,106 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 310 | $10,394 |
| Azelastine Hcl | 403 | $9,658 |
| Pulmicort FlexhalerBudesonide | 29 | $9,416 |
| Epinephrine | 32 | $8,667 |
| Wixela InhubFluticasone Propion/Salmeterol | 33 | $7,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $545 | $914,24819 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta | $1,769 | $175,124169 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl | $189 | $37,53092 claims |
| Boehringer IngelheimSpiriva Respimat | $216 | $36,03345 claims |
| AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort | $1,317 | $29,33167 claims |
| Hikma Pharmaceuticals USAEpinephrine | $32 | $8,66732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 51 pediatric allergy/immunology providers in New York.
Other pediatric allergy/immunology in Buffalo
- Heather LehmanBuffalo$368K
- Viveka de GuerraBuffalo$237
- Sujatha RameshBuffalo$121
- Wayne ShrefflerNew York$2.9M
- Michael MarcusBrooklyn$1.3M
- Kirsi Jarvinen-SeppoRochester$1.2M
- Julie WangNew York$882K
- Blanka KaplanGreat Neck$304K
- Amanda CoxNew York$301K
- Vincent BonaguraGreat Neck$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.